Search results
Order by most recent / most popular / relevance
Results: 11-20 of 196
Judicial review brought outside time period and no vested right to NOC
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This decision relates to the consideration by the Minister of Health of Apotex’ submission for a Notice of Compliance (NOC) for omeprazole magnesium
Definition of “innovative drug” does not include variations
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 16 2013
Health Canada has announced Updated Screening Criteria for Generic Drug Submissions. It has also published a Sponsor Attestation Checklist for ANDS
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 9 2013
Health Canada has announced a Consultation on the new Prescription Drug List. The consultation is open for comment until March 7, 2013. Health Canada has
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 17 2012
Health Canada has started a Consultation on its Public Clinical Trials Database. The Consultation is open for comment until February 13, 2013. Health
Impeachment action in respect of expired patent allowed to continue
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 17 2012
Apotex commenced an impeachment action in respect of two patents. Warner-Lambert brought a motion seeking to dismiss the action as it related to one patent
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 12 2012
The PMPRB has published Rules of Practice and Procedure in the Canada Gazette II
Court of Appeal considers comity as it applies to NOC proceedings
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 4 2012
Apotex v
Leave for appeal dismissed with costs
- Borden Ladner Gervais LLP
- -
- Canada
- -
- December 4 2012
The Supreme Court of Canada dismissed Wyeth’s application for leave to appeal the decision of the Federal Court of Appeal which permitted ratiopharm’s s. 8 proceeding, claiming damages from Wyeth, to continue after it amalgamated with Teva
Other industry news
- Borden Ladner Gervais LLP
- -
- Canada
- -
- November 28 2012
Minister Aglukkaq announces new rules to address prescription drug abuse
Current Search
- Workarea - Healthcare
- Author - Beverley Moore
- Jurisdiction - Canada